INFO & CONTACTS:  +39 02 2390 1

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1TPS ≥50%

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Lo Russo Giuseppe

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: MK-1084 Pembrolizumab

Pathologies: Lung cancer

ClinicalTrials.gov: Read the details about clinical trials

This clinical trial will evaluate the KRAS G12C mutation inhibitor, MK-1084, in combination with pembrolizumab versus placebo plus pembrolizumab as first-line treatment of metastatic NSCLC positive for the KRAS G12C mutation with PD-L1 TPS ≥50%. 

The study comprises 2 treatment arms: 

  • Arm A: Pembrolizumab + MK1084 
  • Arm B: Pembrolizumab+ placebo 

Last update: 09/06/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe